Loading…
Loading…
Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).
Revolution Medicines maintains a strong buy rating following FDA approval of RASONQUE for 2nd-line metastatic PDAC, with significant expansion opportunities ahead. Company's pipeline includes zoldonrasib, targeting G12D-mutant PDAC and NSCLC, with two pivotal phase 3 trials underway in 1st-line settings, leveraging strong prior efficacy data. The company holds $3.9B in cash, supported by recent financings and a $2B Royalty Pharma agreement, providing at least 12 months of operational runway.
Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only projected in 2029 as revenue ramps from global expansion.
Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.
It's a cancer medication with immense potential. In clinical testing, the pill was shown to double the survival rate of pancreatic cancer patients.
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript